大參林(603233.SH):鄖西聯耘等股東已合計減持916.93萬股
格隆匯 11 月 13日丨大參林(603233.SH)公佈,公司於2020年8月28日披露了《大參林醫藥集團股份有限公司關於公司股東減持股份計劃的公告》,鄖西聯耘、鄖西智威、鄖西鼎燁、鄖西拓宏將通過集中競價方式或大宗交易方式減持其各持有公司股份不超過421.2萬股,即減持各持有不超過公司總股本的0.64%。上述四位股東合計擬減持1684.8萬股,佔公司總股本的2.57%。截止2020年11月11日,上述股東合計減持916.93萬股(佔公司總股本的1.40%),減持數量過半,減持計劃尚未實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.